Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 555-563

  Smith, Kimberly Y ^a   Tierney, Camlin ^b   Mollan, Katie ^b,c   Venuto, Charles S ^d   Budhathoki, Chakra ^b   Ma, Qing ^e   Morse, Gene D ^e   Sax, Paul ^f   Katzenstein, David ^g   Godfrey, Catherine ^h   Fischl, Margaret ⁱ   Daar, Eric S ^j   Collier, Ann C ^k  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j HARBOR UCLA MEDICAL CENTER   (United States)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

abacavir; atazanavir; efavirenz; sex; tenofovir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR; RITONAVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROTOXICITY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; PUERTO RICO; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PUERTO RICO; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84893309602     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit747     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013; 1-240. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/ AdultandAdolescent/0. Accessed 17 June 2013.
2. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 2012; 308:387-402.
3. Centers for Disease Control. HIV surveillance report: diagnoses of HIV infection and AIDS in the United States and dependent areas. 2009.
4. Department of Health and Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx? GuidelineID=9&ClassID=2). Accessed 17 June 2013.
5. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452-61.
6. Bosch RJ, Bennett K, Collier AC, et al. Pre-treatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:268-77.
7. Soon G, Min M, Struble KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS 2012; 26.
8. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
9. Daar E, Tierney C, Fischl M, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1. Ann Intern Med 2011; 154:445-56.
10. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-201.
11. Keil K, Hochreiter J, DiFrancesco R, et al. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther Drug Monit 2007; 29: 103-9.
12. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline-and treatmentrelated factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-34.
13. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
14. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106.
15. Riddler SA, Haubrich R, DiRienzo G, et al. Effect of baseline characteristics on treatment outcomes in ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. In: 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 February 2008. Abstract 776.
16. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care 2000; 12:255-66.
17. Cernohous P, Bernstein B, Mosley J, et al. Safety and efficacy of lopinavir/ritonavir in women in a phase III study of antiretroviral-naive subjects. In: 14th IAC, Barcelona, Spain, 2002. AbstractWePeB5972.
18. Venuto C, Mollan K, Ma Q, et al. Atazanavir pharmacokinetics and efficacy and safety outcomes by sex in AIDS Clinical Trials Group Study 5202 (A5202). In: 19th International AIDS Conference, Washington, DC, 22-27 July 2012. Abstract TUPDB0101.
19. Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46:547-54.
20. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL. pdf. Accessed 16 September 2013.